Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

US Discretionary Spending Ishares Evolved ETF (IEDI)

US Discretionary Spending Ishares Evolved ETF (IEDI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
ETFs in Focus as Walmart Gears Up to Report Q3 Earnings
ETFs in Focus as Walmart Gears Up to Report Q3 Earnings Zacks Investment Research - Mon Nov 18, 12:32PM CST

The world's largest brick-and-mortar retailer — Walmart WMT — is scheduled to report its third-quarter fiscal 2025 results on Nov. 19, before market open. Let’s take a closer look at its fundamentals...

IEDI : 53.37 (+0.33%)
VDC : 214.72 (+0.69%)
RTH : 224.17 (+0.72%)
FSTA : 50.17 (+0.64%)
XLP : 80.52 (+0.70%)
WMT : 84.08 (-0.20%)
Consumer Cyclical (names I - Z) - Rollins, Inc_ phone and website- by T_Schneider via Shutterstock
Rollins Stock: Is Wall Street Bullish or Bearish? Barchart - Fri Aug 23, 5:28AM CDT

Rollins has outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

ROL : 50.05 (+0.28%)
$SPX : 5,893.62 (+0.39%)
IEDI : 53.37 (+0.33%)
MS : 133.78 (-0.21%)

Barchart Exclusives

Buy This Pharma Stock to Bet on the Next Blockbuster Weight-Loss Drug Barchart - 12 minutes ago
A shocking study in The Lancet showed that nearly three-quarters of U.S. adults are overweight or obese. Chances are that by 2050, there will be 260 million overweight Americans. We already have GLP-1 drugs, and amylin-based drugs are next. Novo Nordisk's compound, Cagrilintide, will be combined with semaglutide in its next blockbuster drug, CagriSema. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot